Related Experiment Video
Updated: Jun 13, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Molecular and clinical prodrome of Parkinson disease: implications for treatment
Anthony H V Schapira1, Eduardo Tolosa
1Department of Clinical Neurosciences, Institute of Neurology, University College Medical School, Rowland Hill Street, London NW3 2PF, UK. a.schapira@medsch.ucl.ac.uk
Abstract:
The development of interventions to slow or prevent progression represents an important aim for current research into Parkinson disease (PD). General agreement prevails that success in this endeavor will depend on a clearer understanding of etiology and pathogenesis, and several important advances have recently been made, particularly in defining the genetic causes of PD. Studies of the biochemical consequences of the mutations that cause familial PD, and postmortem brain studies of idiopathic, sporadic PD, have highlighted mitochondrial dysfunction, oxidative stress, and protein metabolism by the ubiquitin-proteasomal and autophagy systems as being central to pathogenesis. In parallel with advances in etiopathogenesis, a clearer perception has developed of the clinical prodrome of PD, offering an opportunity to identify individuals who are at risk of PD, as well as those in the earliest clinical phase of the disease that might even precede the onset of motor symptoms. These populations are potentially the most suitable in which to test new protective therapies, and to study potential peripheral markers of disease progression. The awareness of the early symptomatic period of PD also raises the possibility of providing treatments that not only improve motor function but might also favorably modify outcome.
Insights
Research into Parkinson disease (PD) focuses on interventions to slow progression. Advances in understanding genetic causes, mitochondrial dysfunction, and early disease detection offer new therapeutic opportunities.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Parkinson disease (PD) research aims to develop interventions for slowing progression.
- Understanding PD etiology and pathogenesis is crucial for successful intervention development.
- Recent advances include defining genetic causes and identifying key pathological pathways.
Purpose of the Study:
- To highlight recent advances in understanding Parkinson disease (PD) etiology and pathogenesis.
- To discuss the potential of targeting early disease stages for therapeutic intervention.
- To explore the identification of at-risk individuals and early-stage patients for clinical trials.
Main Methods:
- Review of genetic studies on familial PD.
- Analysis of biochemical consequences of PD-related mutations.
- Examination of postmortem brain studies in sporadic PD.
- Investigation of clinical prodromal and early symptomatic phases of PD.
Main Results:
- Mitochondrial dysfunction, oxidative stress, and protein metabolism (ubiquitin-proteasomal and autophagy systems) are central to PD pathogenesis.
- A clearer perception of the clinical prodrome of PD allows for early identification of at-risk individuals.
- Early symptomatic PD detection precedes motor symptoms, offering a window for intervention.
Conclusions:
- Understanding PD pathogenesis provides a foundation for developing neuroprotective therapies.
- Identifying individuals in the prodromal or early symptomatic stages is critical for testing new interventions.
- Early therapeutic interventions may not only improve motor function but also favorably modify disease outcome.
Related Concept Videos
01:24Parkinson Disease l: Introduction
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
01:15Parkinson's Disease: Overview
01:11Alterations in Muscle Tone lll
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...